Open AccessIncidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study
Author(s) -
J. Moore,
Stephanie Stroever,
Patricia E. Rondain,
Robyn Scatena
Publication year - 2021
Publication title -
journal of global infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 25
eISSN - 0974-8245
pISSN - 0974-777X
DOI - 10.4103/jgid.jgid_358_20
Subject(s) - tocilizumab , medicine , hazard ratio , retrospective cohort study , cumulative incidence , confidence interval , proportional hazards model , confounding , incidence (geometry) , cohort , cohort study , disease , physics , optics
Immunosuppressive agents are theorized to target the cytokine storm syndrome in COVID-19. However, the downstream effects regarding susceptibilities to secondary infection risk remains unknown. This study seeks to determine risk differences for secondary infections among COVID-19 patients who did and did not receive tocilizumab.